

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 2

Application Number

10/798,037

Filing Date

03-11-2004

First Named Inventor

Robbins, Jeffrey

Art Unit

1632

Examiner Name

Attorney Docket Number

CHM02-GN054

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM		KELLER et al; Genetics of familial cardiomyopathies and arrhythmias; Swiss Med Wkly, 2002, Jul 27; 132(29-20): 401-407; Switzerland	
		CHARRON et al; Cooperative Interaction between GATA-4 and GATA-6 Regulates...; Mol Cell Biol 1999, 19: 4355-4356; Canada	
		PATEL et al; Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis...; Circulation 2001, 104: 317-324; USA	
		CHEN et al; Ventricular muscle-restricted targeting of the RXRa gene reveals ...; Development 1998, 125: 1943-1949; USA and Great Britain	
		MINAMINO et al; Inducible Gene Targeting in Postnatal Myocardium by Cardiac-Specific...; Circ Res 2001, 88: 587-592; USA	
		SOHAL et al; Temporally Regulated and Tissue-Specific Gene Manipula- tions in the Adult...; Circ Res 2001, 89: 20-25; USA and Canada	
		NAGUEH et al; Tissue Doppler Imaging Consistently Detects Myocardial Contraction...; Circulation 2000, 102: 1346-1350; USA	
		JAMES et al; Transgenic Rabbits Expressing Mutant Essential Light Chain do not...; J Mol Cell Cardiol 2002, 34: 873-882; USA	
		MARIAN et al; A transgenic rabbit model for human hypertrophic cardiomyopathy; J Clin Invest 1999, 104: 1683-1692; USA	
SM		HAHN et al; Ischemic Protection and Myofibrillar Cardiomyopathy; Circ Res 2002, 91: 741-748; USA	


Examiner
SignatureDate
Considered

9-28-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/P

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number

10/798,037

Filing Date

03-11-2004

First Named Inventor

Robbins, Jeffrey

Art Unit

1632

Examiner Name

Attorney Docket Number

CHM02-GN054

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM		ALPERT et al; Molecular mechanics of mouse cardiac myosin isoforms; Am J Physiol Heart Circ Physiol 2002, 283: H1446-54; USA	
		SHAH et al; Adenovirus-Mediated Genetic Manipulation of the Myocardial B-Adrenergic...; J Thoracic Cardio Surgery 2000, 120: 581-585; USA	
		SCHWARTZBAUER et al; The Tumor Suppressor Gene PTEN Can Regulate...; J Biol Chemistry 2001, 276: 35786-93; USA	
		WIGLE et al; Hypertrophic Cardiomyopathy; Circulation 1995, 92: 1680-1692; Canada	
		BRAUNWALD et al; Contemporary Evaluation and Managemen of Hypertrophic...; Circulation 2002, 106: 1312-1316; USA and Switzerland	
		JAMES et al; Genetic Manipulation of the Rabbit Heart via Transgenesis; Circulation 2000, 101: 1715-1721	
		AF192306; Def: Oryctolagus cuniculus slow type myosin heavy chain gene, promoter and partial cds.	
SM		AF192305; Def: Oryctolagus cuniculus alpha myosin heavy chain gene, promoter and partial cds.	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/798,037
Filing Date	03-11-2004
First Named Inventor	ROBBINS, JEFFREY
Art Unit	1636-1632
Examiner Name	
Attorney Docket Number	CHM02-GN054

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Gu		Database GenEmbl, Accession No. AF192305, SANBE et al., 2002, computer printout pages 1-4.	
Gu		Database GenEmbl, Accession No. AF192306, SANBE et al., 2002, computer printout pages 1-5.	

Examiner Signature	<i>ecchen</i>	Date Considered	9-28-03
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.